NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

AVITA Medical, Inc. (RCEL) Stock Analysis

AVITA Medical, Inc. (RCEL) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

RCEL

$11.20

+$0.26 (+2.38%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RCEL with… →

RCEL Key Statistics

As of Sep 4, 2026
Trading
Open
$10.99
Previous Close
$10.94
Day's Range
10.80–11.39
52-Week Range
3.22–11.38
Volume
301.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.02
Valuation
Market Cap
$346.38M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.44
Financials (FY)
Revenue (FY)
$71.61M+11.45%
Net Income (FY)
−$48.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
−56.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.93M
1-Year Return
+161.07%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
461.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RCEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+224.64%
2025−73.05%
2024−6.71%
2023+107.88%
2022−44.91%
2021−35.52%
2020−59.16%
2019+712.50%
2018+4.67%
2017−41.85%
2016 (partial year)+21.85%

As of September 4, 2026.

RCEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$71.61M−$48.59M−67.8%
2024$64.25M−$61.85M−96.3%
2023$50.14M−$35.38M−70.6%
2022$34.42M−$26.67M−77.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$71.61M$58.82M−$42.53M−$48.59M−67.8%
2024$64.25M$55.16M−$56.59M−$61.85M−96.3%
2023$50.14M$42.36M−$42.66M−$35.38M−70.6%
2022$34.42M$28.38M−$27.51M−$26.67M−77.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RCEL Valuation vs Medical Devices Median

Median of 151 stocks
MetricRCELMedical Devices medianvs median
P/S ratio4.582.9854% above
Profit margin−56.96%−1.69%55.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AVITA Medical, Inc. (RCEL) carries a market capitalisation of $346.38M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 226.

RCEL last closed at $11.20 on September 4, 2026. That is +$0.26 (+2.38%) against the previous close. Over the past 52 weeks the price has ranged from $3.22 to $11.38. The latest close sits 247.83% above that 52-week low.

Financial Health

In fiscal 2025, AVITA Medical, Inc. reported revenue of $71.61M. Against the prior fiscal year total of $64.25M, that is a change of +11.45%. The same year closed with a net loss of $48.59M. The reported profit margin is −56.96%. That is 55.3 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −1.44.

Across the 4 fiscal years on file, revenue moves from $34.42M in 2022 to $71.61M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.58. On price-to-sales that is 53.89% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is +161.07%. Across 10 years the annualized return works out at +4.52%. The reported beta is 2.02. Daily returns over the trailing 10 years annualize to a volatility of 78.8%.

Growth & Income

The record shows no dividend for RCEL.

2026 is still running; the price is +224.64% year to date. The strongest complete calendar year on file is 2019 at +712.50%; the weakest is 2025 at −73.05%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

AVITA Medical, Inc. (RCEL) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AVITA Medical, Inc. RCEL $346.38M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. AVITA Medical, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About AVITA Medical, Inc.

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Visit website →